JP2009542762A - 殺生物性組成物に関連する改良 - Google Patents

殺生物性組成物に関連する改良 Download PDF

Info

Publication number
JP2009542762A
JP2009542762A JP2009518833A JP2009518833A JP2009542762A JP 2009542762 A JP2009542762 A JP 2009542762A JP 2009518833 A JP2009518833 A JP 2009518833A JP 2009518833 A JP2009518833 A JP 2009518833A JP 2009542762 A JP2009542762 A JP 2009542762A
Authority
JP
Japan
Prior art keywords
water
biocide
insoluble
carrier
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009518833A
Other languages
English (en)
Japanese (ja)
Inventor
デイヴィッド・ジョン・ダンカルフ
アリソン・ジェーン・フォスター
ジェームス・ロング
スティーブン・ポール・ランナード
ドン・ワン
Original Assignee
ユニリーバー・ナームローゼ・ベンノートシヤープ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニリーバー・ナームローゼ・ベンノートシヤープ filed Critical ユニリーバー・ナームローゼ・ベンノートシヤープ
Publication of JP2009542762A publication Critical patent/JP2009542762A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
JP2009518833A 2006-07-13 2007-06-29 殺生物性組成物に関連する改良 Pending JP2009542762A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0613925.7A GB0613925D0 (en) 2006-07-13 2006-07-13 Improvements relating to nanodispersions
PCT/EP2007/056562 WO2008006714A2 (en) 2006-07-13 2007-06-29 Improvements relating to biocidal compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010131047A Division JP2010202665A (ja) 2006-07-13 2010-06-08 殺生物性組成物に関連する改良

Publications (1)

Publication Number Publication Date
JP2009542762A true JP2009542762A (ja) 2009-12-03

Family

ID=36955583

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2009518832A Pending JP2009542761A (ja) 2006-07-13 2007-06-29 抗寄生虫組成物に関連する改良
JP2009518833A Pending JP2009542762A (ja) 2006-07-13 2007-06-29 殺生物性組成物に関連する改良
JP2009518834A Pending JP2009542763A (ja) 2006-07-13 2007-06-29 製薬組成物に関連する改良
JP2009518831A Pending JP2009542760A (ja) 2006-07-13 2007-06-29 ナノ分散体に関する改良
JP2009518835A Pending JP2009542764A (ja) 2006-07-13 2007-06-29 医薬組成物に関連する改良
JP2009518980A Pending JP2009542795A (ja) 2006-07-13 2007-07-13 医薬組成物の調製
JP2009518978A Pending JP2009542793A (ja) 2006-07-13 2007-07-13 製薬組成物の調製
JP2009518979A Pending JP2009542794A (ja) 2006-07-13 2007-07-13 医薬組成物の調製方法
JP2010131047A Withdrawn JP2010202665A (ja) 2006-07-13 2010-06-08 殺生物性組成物に関連する改良

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009518832A Pending JP2009542761A (ja) 2006-07-13 2007-06-29 抗寄生虫組成物に関連する改良

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2009518834A Pending JP2009542763A (ja) 2006-07-13 2007-06-29 製薬組成物に関連する改良
JP2009518831A Pending JP2009542760A (ja) 2006-07-13 2007-06-29 ナノ分散体に関する改良
JP2009518835A Pending JP2009542764A (ja) 2006-07-13 2007-06-29 医薬組成物に関連する改良
JP2009518980A Pending JP2009542795A (ja) 2006-07-13 2007-07-13 医薬組成物の調製
JP2009518978A Pending JP2009542793A (ja) 2006-07-13 2007-07-13 製薬組成物の調製
JP2009518979A Pending JP2009542794A (ja) 2006-07-13 2007-07-13 医薬組成物の調製方法
JP2010131047A Withdrawn JP2010202665A (ja) 2006-07-13 2010-06-08 殺生物性組成物に関連する改良

Country Status (17)

Country Link
US (10) US9060937B2 (enExample)
EP (8) EP2040679A2 (enExample)
JP (9) JP2009542761A (enExample)
CN (11) CN101489533A (enExample)
AP (1) AP2008004713A0 (enExample)
AR (4) AR061990A1 (enExample)
AU (9) AU2007271831B2 (enExample)
BR (8) BRPI0714230A2 (enExample)
CA (8) CA2656217A1 (enExample)
CL (4) CL2007002032A1 (enExample)
ES (2) ES2752460T3 (enExample)
GB (1) GB0613925D0 (enExample)
IL (2) IL195911A0 (enExample)
MX (2) MX2009000309A (enExample)
TW (1) TW200812694A (enExample)
WO (8) WO2008006716A2 (enExample)
ZA (7) ZA200900030B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532732A (ja) * 2010-08-05 2013-08-19 ダウ アグロサイエンシィズ エルエルシー 高められた活性を有するメソサイズ粒子の農薬組成物関連出願に対する相互参照

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501833D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Carrier liquids and methods of production thereof
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008022651A1 (en) 2006-08-21 2008-02-28 Antoine Turzi Process and device for the preparation of platelet rich plasma for extemporaneous use and combination thereof with skin and bone cells
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
WO2009081283A2 (en) * 2007-06-18 2009-07-02 Combino Pharm, S.L. Aqueous formulations of acetaminophen for injection
WO2009047634A2 (en) * 2007-06-18 2009-04-16 Combino Pharm, S.L. Aqueous formulations of acetaminophen for injection
PL2200588T3 (pl) * 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
TR200800634A2 (tr) * 2008-01-30 2009-02-23 Takka Sevgi̇ Uzatılmış salım sağlayan fluvastatin tablet.
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
KR101376397B1 (ko) * 2008-07-11 2014-03-20 닛뽕소다 가부시키가이샤 서방성 제제 조성물의 제조 방법
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
EP2348834B1 (en) 2008-09-25 2018-04-18 Vive Crop Protection Inc. Methods to produce polymer nanoparticles and formulations of active ingredients
FR2938433B1 (fr) * 2008-11-19 2011-09-09 Francois Fauran Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
WO2010082840A1 (en) * 2008-12-12 2010-07-22 Tim Tech Chemicals Limited Compositions for the treatment of timber and other wood substrates
EP2243477A1 (de) * 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
CN105832678A (zh) 2009-05-27 2016-08-10 株式会社三养生物制药 生物利用度提高的包含难溶性药物的微球及其制备方法
HUP0900376A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate candesartan cilexetil composition
HUP0900384A2 (en) * 2009-06-19 2011-01-28 Nangenex Nanotechnologiai Zartkoerueen Muekoedoe Reszvenytarsasag Nanoparticulate olmesartan medoxomil compositions
WO2010151080A2 (ko) * 2009-06-25 2010-12-29 진양제약 주식회사 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2011026125A2 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
JP5498769B2 (ja) * 2009-12-04 2014-05-21 花王株式会社 脂溶性薬物内包ナノ粒子の製造方法
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
WO2011121515A1 (en) 2010-03-29 2011-10-06 Firmenich Sa Spray-dried crystalline active ingredient
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
US20130196852A1 (en) * 2010-10-05 2013-08-01 Iota Nanosolutions Limited Processes for preparing improved compositions
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
JP2013001771A (ja) * 2011-06-14 2013-01-07 Neos Co Ltd 液状カビ防除洗浄剤組成物
RU2469536C1 (ru) * 2011-06-16 2012-12-20 Государственное бюджетное учреждение Республики Башкортостан "Научно-исследовательский технологический институт гербицидов и регуляторов роста растений с опытно-экспериментальным производством Академии наук Республики Башкортостан" Фунгицидное средство и способ его получения
JP6336902B2 (ja) 2011-06-22 2018-06-06 ビョーメ バイオサイエンシズ ピーブイティー．リミテッド コンジュゲートベースの抗真菌性および抗菌性プロドラッグ
US9686979B2 (en) 2011-08-23 2017-06-27 Vive Crop Protection Inc. Pyrethroid formulations
GB201115079D0 (en) * 2011-08-31 2011-10-19 Iota Nanosolutions Ltd Method of preparing carrier liquids
GB201115635D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
GB201115633D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
GB201115634D0 (en) 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir
US8609684B2 (en) * 2011-12-12 2013-12-17 PruGen IP Holdings, Inc. Solubilization and bioavailability of acetaminophen
JP6062454B2 (ja) 2011-12-22 2017-01-18 ヴァイヴ クロップ プロテクション インコーポレイテッドＶｉｖｅ Ｃｒｏｐ Ｐｒｏｔｅｃｔｉｏｎ Ｉｎｃ． ストロビルリン配合物
IN2014DN10322A (enExample) * 2012-05-16 2015-08-07 Mewa Singh
ES2698611T3 (es) 2012-07-12 2019-02-05 SpecGx LLC Composiciones farmacéuticas disuasorias del abuso y de liberación prolongada
US20140073678A1 (en) * 2012-09-12 2014-03-13 Monosol Rx, Llc Anti-pain and anti-nausea and/or vomiting combinatorial compositions
US20160128944A1 (en) 2013-06-04 2016-05-12 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN105828833A (zh) 2013-10-21 2016-08-03 萨克生物研究学院 突变的成纤维细胞生长因子（fgf）1及使用方法
CN111904924A (zh) * 2013-11-13 2020-11-10 财团法人国际教育基金会 化合物降低对乙酰氨基酚引起的肝毒性的用途及复方组合
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
MX2016011517A (es) 2014-03-07 2017-04-13 Univ Arizona Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico.
EP2952208A1 (en) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalcoholic system for nail treatment
EP3154528B1 (en) 2014-06-11 2023-04-05 SpecGx LLC Spray dried compositions having different dissolution profiles and processes for their preparation
CN104042626A (zh) * 2014-07-01 2014-09-17 李绍明 杀菌抑菌剂
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3237159B1 (en) * 2014-12-23 2019-05-01 Dow Global Technologies LLC Treated porous material
CN107205935A (zh) * 2015-01-20 2017-09-26 默克专利股份有限公司 用聚乙烯醇作载体聚合物的化合物固体分散体
CN104798772B (zh) * 2015-03-13 2017-05-24 中国农业科学院农业环境与可持续发展研究所 一种农药纳米固体分散体及其制备方法
EP3316865A4 (en) 2015-07-02 2019-01-23 Civitas Therapeutics, Inc. TRIPTAN POWDER FOR PULMONARY ADMINISTRATION
WO2017015013A1 (en) * 2015-07-17 2017-01-26 The Board Of Regents Of The University Of Oklahoma Licofelone derivatives and methods of use
CN105145553A (zh) * 2015-10-12 2015-12-16 广西田园生化股份有限公司 一种难溶农药的固体分散体组合物
WO2017133868A1 (de) * 2016-02-02 2017-08-10 Evonik Degussa Gmbh Pulverförmige formulierungen von grenzflachenaktiven substanzen auf festen, wasserlöslichen tragern, verfahren zu deren herstellung sowie deren verwendung
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US20190321310A1 (en) 2016-06-16 2019-10-24 The University Of Liverpool Chemical composition
RU2619249C1 (ru) * 2016-11-07 2017-05-12 Федеральное государственное бюджетное учреждение науки Институт химии твердого тела и механохимии Сибирского отделения Российской академии наук (ИХТТМ СО РАН) Композиция для протравливания семян и способ её получения
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
EP3601301A1 (en) 2017-03-31 2020-02-05 The University of Liverpool Prodrug compositions
TWI725314B (zh) * 2017-06-15 2021-04-21 松瑞製藥股份有限公司 活性成分粒子的製備方法
EP3672411A4 (en) 2017-08-25 2021-05-19 Vive Crop Protection Inc. MULTI-COMPONENT, SOIL APPLICABLE PESTICIDAL COMPOSITIONS
US20210361639A1 (en) 2018-03-02 2021-11-25 The University Of Liverpool Solid compositions of actives, processes for preparing same and uses of such solid compositions
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
WO2020072805A1 (en) 2018-10-04 2020-04-09 Rutgers, The State University Of New Jersey Methods of reducing type 2 cytokine-mediated inflammation using neuromedin peptides
WO2020135600A1 (zh) * 2018-12-28 2020-07-02 南京善思生物科技有限公司 纳米农药制剂及其制备方法
CN109846821B (zh) * 2019-01-03 2021-07-06 昆药集团股份有限公司 一种蒿甲醚纳米制剂及其制备方法
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
CN110074993A (zh) * 2019-06-05 2019-08-02 山东大学 一种制备紫外吸收剂纳米颗粒的方法
US20230133037A1 (en) * 2019-06-28 2023-05-04 Solstar Pharma Extended release gastroretentive formulation against helicobacter pylori
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
CN114615889A (zh) * 2019-10-28 2022-06-10 组合化学工业株式会社 农药组合物及其制造方法
WO2021146625A1 (en) 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of crx-autosomal dominant retinopathies
WO2021225781A2 (en) 2020-05-07 2021-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
IT202000022789A1 (it) 2020-09-28 2020-12-28 Vitop Moulding Srl Rubinetto erogatore provvisto di sistema di collocamento, bloccaggio e orientamento su scatole di tipo Bag-In-Box
GB202115049D0 (en) 2021-10-20 2021-12-01 Univ Liverpool Chemical Compositions
WO2023196898A1 (en) 2022-04-07 2023-10-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta globin mimetic peptides and their use
CN114732009B (zh) * 2022-06-13 2022-08-23 山东百农思达生物科技有限公司 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration
GB202304657D0 (en) 2023-03-29 2023-05-10 Univ Liverpool Atovaquine compositions

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193703A (ja) * 1989-08-17 1991-08-23 Shell Internatl Res Maatschappij Bv 固体農薬組成物、その製造方法およびその使用
WO1997013503A1 (en) * 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying
JP2005504090A (ja) * 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
JP2005507427A (ja) * 2001-11-07 2005-03-17 ビーエーエスエフ アクチェンゲゼルシャフト 作物保護剤を含有するナノ粒子
JP2005507428A (ja) * 2001-11-07 2005-03-17 ビーエーエスエフ アクチェンゲゼルシャフト シニドン−エチルを含有する作物保護固形製剤及び対応する分散液
WO2005044221A2 (de) * 2003-10-31 2005-05-19 Bayer Technology Services Gmbh Feste wirkstoff-formulierung
WO2005054122A1 (en) * 2003-12-05 2005-06-16 Bio-Synectics Inc. Method for preparing nano-scale or amorphous particle using solid fat as a solvent
JP2005519869A (ja) * 2001-10-18 2005-07-07 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト 活性成分粉剤

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB501835A (en) 1936-05-29 1939-03-02 Siemens Ag Process and apparatus for reducing the power required for the mechanical treatment of movable masses
GB1305024A (enExample) * 1969-07-10 1973-01-31
GB1554662A (en) * 1976-05-05 1979-10-24 Inverni Della Beffa Spa Polyhydroxyphenylchromanones
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
DE3439482A1 (de) * 1984-10-27 1986-05-07 Röhm GmbH, 6100 Darmstadt Verfahren zur beschichtung von substraten mit kratzfesten, nichtreflektierenden ueberzuegen
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US5160530A (en) * 1989-01-24 1992-11-03 Griffin Corporation Microencapsulated polymorphic agriculturally active material
JP3067810B2 (ja) * 1990-12-21 2000-07-24 中外製薬株式会社 経口投与用ｏ／ｗ型エマルジョンの乾燥粉末製造法
GB9304294D0 (en) * 1993-03-03 1993-04-21 Zeneca Ltd Herbicidal compositions
DE4329446A1 (de) * 1993-09-01 1995-03-02 Basf Ag Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
TW318777B (enExample) * 1995-06-29 1997-11-01 Novartis Ag
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
WO1998029098A1 (en) * 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
JP4183279B2 (ja) * 1997-04-15 2008-11-19 アール ピー シェーラー テクノロジーズ インコーポレーテッド 医薬用加水分解セルロース顆粒
EP1080720A4 (en) * 1998-03-05 2002-06-05 Nippon Shinyaku Co Ltd FAT EMULSIONS FOR INHALATIVE ADMINISTRATION
JPH11322587A (ja) 1998-05-18 1999-11-24 Sumitomo Chem Co Ltd 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物
JP2002534371A (ja) * 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
GB9904012D0 (en) 1999-02-22 1999-04-14 Zeneca Ltd Agrochemical formulation
ATE312601T1 (de) 1999-05-27 2005-12-15 Acusphere Inc Poröse arzneistoffmatrizen und deren herstellungsverfahren
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
EP1246668B1 (en) 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR100694667B1 (ko) * 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
WO2001089484A2 (en) 2000-05-22 2001-11-29 Verion, Inc. Method for increasing the compressibility of poorly binding powder materials
US6932963B2 (en) * 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
IT1318618B1 (it) 2000-07-10 2003-08-27 A C R Applied Coating Res S A Microsfere bioadesive a rilascio rapido per la somministrazionesublinguale di principi attivi.
AU2002224526A1 (en) * 2000-07-24 2002-02-05 Ono Pharmaceutical Co. Ltd. Freeze-dried preparation of n-(o-(p-pivaloyloxybenzenesulfonylamino)benzoyl)glycine monosodium salt tetrahydrate and process for producing the same
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
DE60129573T2 (de) * 2000-09-20 2008-04-17 Jagotec Ag Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
CA2436418A1 (en) * 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Process for production of nanoparticles and microparticles by spray freezing into liquid
US6355675B1 (en) 2001-05-15 2002-03-12 Isp Investments Inc. Emulsifiable concentrate of a water-insoluble fungicide
IL159129A0 (en) 2001-06-01 2004-05-12 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
HUP0400264A2 (hu) * 2001-06-22 2004-08-30 Pfizer Products Inc. Alacsony oldékonyságú és/vagy savra érzékeny hatóanyagokat és semlegesített savas polimereket tartalmazó gyógyszerkészítmények és eljárás az előállításukra
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
US7836477B2 (en) * 2001-08-21 2010-11-16 Sony Corporation Information processing system, information processing apparatus and method
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP1474144B1 (en) * 2002-02-01 2008-08-06 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
US20040028505A1 (en) * 2002-06-07 2004-02-12 Bilbrey Robert A. Document tape binding system with automatic tape feed, tape indicia sensing, spine printing method and post-bind automation mechanisms
AU2003245313A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20030017208A1 (en) * 2002-07-19 2003-01-23 Francis Ignatious Electrospun pharmaceutical compositions
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
CN1176649C (zh) 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
EP1569620A4 (en) * 2002-10-30 2006-03-22 Spherics Inc NANOPARTICULAR BIOACTIVE AGENTS
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
WO2004060396A2 (en) * 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
US20060210620A1 (en) * 2003-01-21 2006-09-21 Kumra Pannanchukunnath M Co-precipitated amorphous losartan and dosage forms comprising the same
US20040197301A1 (en) * 2003-02-18 2004-10-07 Zhong Zhao Hybrid polymers and methods of making the same
EP1594470A4 (en) * 2003-02-19 2007-10-17 Biovail Lab Int Srl QUICK ABSORPTION 5-HT SELECTIVE AGONIST FORMULATIONS
WO2004075921A1 (en) * 2003-02-26 2004-09-10 Vrije Universiteit Brussel Inclusion complex of artemisinin or derivates thereof with cyclodextrins
RU2005134364A (ru) 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
WO2005014043A1 (en) * 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
US7687167B2 (en) * 2003-07-18 2010-03-30 Panasonic Corporation Power supply unit
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10351004A1 (de) * 2003-10-30 2005-05-25 Basf Ag Nanopartikuläre Wirkstoffformulierungen
ATE500819T1 (de) * 2003-12-31 2011-03-15 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
IL160095A0 (en) * 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
JP2005298347A (ja) * 2004-04-06 2005-10-27 Yoshiaki Kawashima 吸入製剤及びその製造方法
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
WO2005104864A1 (en) * 2004-04-28 2005-11-10 Unilever N.V. Edible oil containing statins
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
ES2339682T3 (es) 2004-06-01 2010-05-24 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Procedimiento para la preparacion de la forma amorfa de un farmaco.
DE102004031298A1 (de) 2004-06-28 2006-01-12 Basf Ag Wässrige Dispersionen schwer wasserlöslicher oder wasserunlöslicher Wirkstoffe und daraus hergestellte Trockenpulver enthaltend mindestens ein Polyethergruppen enthaltendes Polymer als Schutzkolloid
CN101031285A (zh) * 2004-10-01 2007-09-05 卫材R&D管理有限公司 含有微粒的组合物及其制备方法
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
AU2006204083A1 (en) 2005-01-06 2006-07-13 Elan Pharma International Ltd. Nanoparticulate candesartan formulations
GB0501835D0 (en) * 2005-01-28 2005-03-09 Unilever Plc Improvements relating to spray dried compositions
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193703A (ja) * 1989-08-17 1991-08-23 Shell Internatl Res Maatschappij Bv 固体農薬組成物、その製造方法およびその使用
WO1997013503A1 (en) * 1995-10-13 1997-04-17 The Penn State Research Foundation Synthesis of drug nanoparticles by spray drying
JP2005504090A (ja) * 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
JP2005519869A (ja) * 2001-10-18 2005-07-07 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト 活性成分粉剤
JP2005507427A (ja) * 2001-11-07 2005-03-17 ビーエーエスエフ アクチェンゲゼルシャフト 作物保護剤を含有するナノ粒子
JP2005507428A (ja) * 2001-11-07 2005-03-17 ビーエーエスエフ アクチェンゲゼルシャフト シニドン−エチルを含有する作物保護固形製剤及び対応する分散液
WO2005044221A2 (de) * 2003-10-31 2005-05-19 Bayer Technology Services Gmbh Feste wirkstoff-formulierung
WO2005054122A1 (en) * 2003-12-05 2005-06-16 Bio-Synectics Inc. Method for preparing nano-scale or amorphous particle using solid fat as a solvent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532732A (ja) * 2010-08-05 2013-08-19 ダウ アグロサイエンシィズ エルエルシー 高められた活性を有するメソサイズ粒子の農薬組成物関連出願に対する相互参照
JP2017061479A (ja) * 2010-08-05 2017-03-30 ダウ アグロサイエンシィズ エルエルシー 高められた活性を有するメソサイズ粒子の農薬組成物 関連出願に対する相互参照

Also Published As

Publication number Publication date
BRPI0714176A2 (pt) 2012-12-25
AU2007271827B2 (en) 2010-10-14
ZA200900030B (en) 2010-04-28
US8821932B2 (en) 2014-09-02
IL195933A (en) 2013-06-27
ZA200900347B (en) 2010-04-28
AU2007274041A1 (en) 2008-01-17
JP2009542764A (ja) 2009-12-03
AR061992A1 (es) 2008-08-10
JP2010202665A (ja) 2010-09-16
CN101516340A (zh) 2009-08-26
CN101489533A (zh) 2009-07-22
US7691873B2 (en) 2010-04-06
AR061991A1 (es) 2008-08-10
MX2009000307A (es) 2009-01-26
WO2008006716A2 (en) 2008-01-17
JP2009542763A (ja) 2009-12-03
JP2009542795A (ja) 2009-12-03
CA2659666A1 (en) 2008-01-17
CA2656223A1 (en) 2008-01-17
US20100008995A1 (en) 2010-01-14
US20090239749A1 (en) 2009-09-24
CL2007002032A1 (es) 2008-01-18
CN101489531A (zh) 2009-07-22
AU2010201900A1 (en) 2010-06-03
EP2040680B1 (en) 2019-08-07
BRPI0714353A2 (pt) 2013-05-07
US20100015233A1 (en) 2010-01-21
AU2007271828B2 (en) 2010-12-02
US9060937B2 (en) 2015-06-23
WO2008007150A1 (en) 2008-01-17
WO2008007152A3 (en) 2008-03-06
WO2008006713A2 (en) 2008-01-17
CA2657582A1 (en) 2008-01-17
CL2010000516A1 (es) 2010-10-15
CN101489535A (zh) 2009-07-22
AU2007271829B2 (en) 2011-10-27
AU2007271829A1 (en) 2008-01-17
WO2008006712A3 (en) 2009-02-26
AU2007271831B2 (en) 2010-11-18
BRPI0714230A2 (pt) 2013-01-15
ES2741124T3 (es) 2020-02-10
EP2040678A2 (en) 2009-04-01
BRPI0722376A2 (pt) 2012-05-22
AU2007271827A1 (en) 2008-01-17
BRPI0714179A2 (pt) 2012-12-25
AU2007274039A1 (en) 2008-01-17
AU2007271828A1 (en) 2008-01-17
CN101489532A (zh) 2009-07-22
EP2387992A1 (en) 2011-11-23
EP2040679A2 (en) 2009-04-01
JP2009542794A (ja) 2009-12-03
TW200812694A (en) 2008-03-16
US20090304806A1 (en) 2009-12-10
US8945626B2 (en) 2015-02-03
EP2040681B1 (en) 2017-08-09
CL2007002030A1 (es) 2008-01-18
IL195933A0 (en) 2009-09-01
WO2008007151A3 (en) 2008-03-06
CA2656233A1 (en) 2008-01-17
WO2008006715A3 (en) 2008-05-08
GB0613925D0 (en) 2006-08-23
WO2008007151A2 (en) 2008-01-17
JP2009542761A (ja) 2009-12-03
CN102671585A (zh) 2012-09-19
WO2008006713A3 (en) 2008-07-31
EP2269581A1 (en) 2011-01-05
EP2040677B1 (en) 2019-05-08
US20090325995A1 (en) 2009-12-31
CA2656217A1 (en) 2008-01-17
CN101849911A (zh) 2010-10-06
BRPI0714351A2 (pt) 2013-03-19
WO2008006715A2 (en) 2008-01-17
JP2009542760A (ja) 2009-12-03
AU2007271831A1 (en) 2008-01-17
CN101516342A (zh) 2009-08-26
AU2007274040A1 (en) 2008-01-17
EP2040677A2 (en) 2009-04-01
BRPI0714177A2 (pt) 2011-05-03
ZA200900031B (en) 2010-04-28
CN101489534A (zh) 2009-07-22
ZA200900029B (en) 2010-04-28
EP2040680A2 (en) 2009-04-01
CN102631874A (zh) 2012-08-15
ZA200900345B (en) 2010-05-26
EP2040681A2 (en) 2009-04-01
EP2386292A1 (en) 2011-11-16
CL2007002031A1 (es) 2008-01-18
JP2009542793A (ja) 2009-12-03
CA2656229A1 (en) 2008-01-17
CN101516341A (zh) 2009-08-26
US20120135058A1 (en) 2012-05-31
US20100015229A1 (en) 2010-01-21
AU2007271830B2 (en) 2010-11-11
BRPI0714352A2 (pt) 2013-03-19
AR077195A2 (es) 2011-08-10
AU2007271830A1 (en) 2008-01-17
WO2008007152A2 (en) 2008-01-17
WO2008006716A3 (en) 2008-03-13
ZA200900027B (en) 2010-04-28
CA2657548A1 (en) 2008-01-17
CA2657586A1 (en) 2008-01-17
AR061990A1 (es) 2008-08-10
AP2008004713A0 (en) 2008-12-31
WO2008006714A2 (en) 2008-01-17
WO2008006712A2 (en) 2008-01-17
US20100068282A1 (en) 2010-03-18
ES2752460T3 (es) 2020-04-06
US20090175953A1 (en) 2009-07-09
WO2008006714A3 (en) 2008-02-21
ZA200900028B (en) 2010-04-28
IL195911A0 (en) 2009-09-01
US20120134940A1 (en) 2012-05-31
MX2009000309A (es) 2009-01-26
CA2656229C (en) 2014-05-27

Similar Documents

Publication Publication Date Title
AU2007271829B2 (en) Improvements relating to biocidal compositions
Hayles et al. Nanopesticides: a review of current research and perspectives
Dong et al. User-safe and efficient chitosan-gated porous carbon nanopesticides and nanoherbicides
US20170112125A1 (en) Processes for preparing improved compositions
Kumar et al. Synthesis, characterization and on field evaluation of pesticide loaded sodium alginate nanoparticles
Shah et al. Nanotechnology and insecticidal formulations
US20070081947A1 (en) Solid active ingredient formulation
JP2005507427A5 (enExample)
CN101941675A (zh) 纳米颗粒及其制备方法
Zhu et al. Facile pathway to generate agrochemical nanosuspensions integrating super-high load, eco-friendly excipients, intensified preparation process, and enhanced potency
Rehman et al. Nano-enabled agrochemicals for sustainable agriculture
Rehman et al. Application of nanopesticides and its toxicity evaluation through Drosophila model
US8901037B2 (en) Composition having a germination-preventing activity, processes for obtaining said compositions and use thereof
Adetuyi et al. Nanobioinsecticide and Nanoemulsions: Recent Advances
Sheeja et al. Nano-enabled Pesticides: Status and Perspectives
Derbalah et al. Comparative efficacy of solid nano-dispersions and conventional formulations of some insecticides against Spodoptera littoralis,(Boisd.) under laboratory and field conditions
Purkait et al. International Journal of Green and Herbal Chemistry

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100608

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130806